Summary
61 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 17% a year over the last 3 years.
- The share price is below the Bulios Fair Price.
- It bought back its own shares for ¥78.6B in the last fiscal year, 12% of its market value.
What to watch
- It cut its dividend by 43% last year.
- Out of every 100 JPY of revenue, only 2.9 JPY is left as net profit.
- It earns only 3.7 JPY a year on every 100 JPY of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 15.5 JPY for 1 JPY of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (JPY)
Diluted EPS (JPY)
- Analyst estimate
Revenue grew by 9.6% a year over 5 years. Over the last 3 years it grew by 14% a year. For the next fiscal year analysts expect revenue to grow by 0.1%. Earnings per share grew by 17% a year over the last 3 years.
Growth in detailDoes it make money?
PoorlyWhere 100 JPY of revenue goes
- Cost of sales 69 JPY
- Sales and administration 27 JPY
- Taxes and other 1.7 JPY
- Net profit 2.4 JPY
Net profit, industry median (Medical - Pharmaceuticals) 4.8 JPY
Out of every 100 JPY of revenue, 2.4 JPY is left as net profit.
Profitability in detailIs it financially healthy?
Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 1.74%
- Paid out of profit
- 27%
You receive $0.30 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Neutral- Buy 0
- Hold 1
- Sell 0
No analyst has published a price target.
0.0% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.